Clinical Efficacy, Survival, and Adverse Reaction Evaluation of Immune Checkpoint Inhibitor in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis

Table 1

Basic characteristics of literature.

Include the literature	Year of publication	(C/T)	Intervention method		Outcome index	Course of treatment	Whether it is random or not	Whether it is blind or not
			C	T
Zheng Guili [17]	2021	40/40	FOLFOX4Chemotherapy regimen	FOLFOX4Chemotherapy regimen+PD-1Inhibitor	①②③	6 courses of treatment	Yes	No
Liang Lijun [18]	2022	43/43	Irinotecan/paclitaxel + tigio + apatinib mesylate	Irinotecan/paclitaxel + tigio + apatinib mesylate + Carrell monoclonal antibody	①④⑤	24 weeks	Yes	No
Shen Wang [19]	2022	45/43	Alotinib	Alotinib + Carrilizu monoclonal antibody	①②⑤	4 courses of treatment	Yes	No
Zhang Lianhua [20]	2021	40/40	Docetaxel + irinotecan hydrochloride + tigio	Docetaxel + irinotecan hydrochloride + tigio + Carrell monoclonal antibody	①③⑤	3 cycles	No	No
Tu Huiyang [21]	2021	38/38	XELOX/FOLFOX chemotherapy regimen	XELOX/FOLFOX chemotherapy regimen + pablizumab	①②③	3 cycles	Yes	No
Wang Junsong [22]	2022	40/42	Oxaliplatin + capecitabine	Oxaliplatin + capecitabine + Pabolizhu monoclonal antibody	①④⑤	To the progress of the disease	Yes	No

Note: C: control group; T: study group; ①: clinical efficacy; ②: immune function index; ③: tumor marker level; ④: survival time; ⑤: adverse reactions.